The prostate cancer drug developer Dendreon is seeking Chapter 11 bankruptcy protection and says it has reached a financial restructuring agreement with investors holding more than $520 million in debt. The Seattle company listed more than $664 million in total debts and $364.6 million in assets in a U.S. Bankruptcy Court filing.

Click here to read original article